Explore the words cloud of the SLIM project. It provides you a very rough idea of what is the project "SLIM" about.
The following table provides information about the project.
Coordinator |
CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH
Organization address contact info |
Coordinator Country | Austria [AT] |
Project website | https://cemm.at/research/projects/fellowships/ec-msca-postdoc-fellowship-slim/ |
Total cost | 178˙156 € |
EC max contribution | 178˙156 € (100%) |
Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
Code Call | H2020-MSCA-IF-2015 |
Funding Scheme | MSCA-IF-EF-ST |
Starting year | 2016 |
Duration (year-month-day) | from 2016-07-01 to 2018-06-30 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH | AT (WIEN) | coordinator | 178˙156.00 |
Less than 25% of patients diagnosed with acute myeloid leukemia (AML) survive longer than 5 years. Current treatment regimen are based on non-specifically acting cytotoxic drugs that cause severe side effects. More effective and more specific, targeted therapies are thus needed. Progress, however, has long been hampered by a lack of understanding of the molecular vulnerabilities of the disease.
We here propose to identify and study synthetic lethal interactions with mutations in nucleophosmin 1 (NPM1) in AML. Up to 35% of AML patients bear mutations in NPM1 leading to a localization of this nucleolar protein to the cytoplasm and a characteristic change in gene expression pattern. Moreover, NPM1 mutations appear to be driver events and stable over multiple courses of therapy and relapse. Identifying cellular pathways or proteins that are essential in an NPM1 mutated background but not in NPM1 wild type cells may thus not only contribute to a better understanding of NPM1 biology but also yield entry points for the development of drugs that selectively kill NPM1 mutated AML cells.
We will take an integrated chemical biology approach to first identify small molecules that selectively kill NPM1 mutated over NPM1 wild type cells and then elucidate their mode of action to gain insight into the underlying biology. This project thus uniquely builds on the longstanding experience of the host laboratory and institute in chemical screening, the elucidation of the mode of action of small molecules and in hematological malignancies.
The proposal is designed to complement the experienced researchers current knowledge in chemical synthesis, assay development, solid tumor biology and small animal imaging techniques to become a well-rounded chemical biologist with a disease focus on solid and liquid cancers. The hosting institution will gain from the researcher´s chemical expertise and find opportunities to expand its network of international collaborations.
year | authors and title | journal | last update |
---|---|---|---|
2017 |
Berend Snijder, Gregory I Vladimer, Nikolaus Krall, Katsuhiro Miura, Ann-Sofie Schmolke, Christoph Kornauth, Oscar Lopez de la Fuente, Hye-Soo Choi, Emiel van der Kouwe, Sinan Gültekin, Lukas Kazianka, Johannes W Bigenzahn, Gregor Hoermann, Nicole Prutsch, Olaf Merkel, Anna Ringler, Monika Sabler, Georg Jeryczynski, Marius E Mayerhoefer, Ingrid Simonitsch-Klupp, Katharina Ocko, Franz Felberbauer, Leonhard Müllauer, Gerald W Prager, Belgin Korkmaz, Lukas Kenner, Wolfgang R Sperr, Robert Kralovics, Heinz Gisslinger, Peter Valent, Stefan Kubicek, Ulrich Jäger, Philipp B Staber, Giulio Superti-Furga Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study published pages: e595-e606, ISSN: 2352-3026, DOI: 10.1016/S2352-3026(17)30208-9 |
The Lancet Haematology 4/12 | 2019-06-13 |
2017 |
Gregory I Vladimer, Berend Snijder, Nikolaus Krall, Johannes W Bigenzahn, Kilian V M Huber, Charles-Hugues Lardeau, Kumar Sanjiv, Anna Ringler, Ulrika Warpman Berglund, Monika Sabler, Oscar Lopez de la Fuente, Paul Knöbl, Stefan Kubicek, Thomas Helleday, Ulrich Jäger, Giulio Superti-Furga Global survey of the immunomodulatory potential of common drugs published pages: 681-690, ISSN: 1552-4450, DOI: 10.1038/nchembio.2360 |
Nature Chemical Biology 13/6 | 2019-06-13 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SLIM" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SLIM" are provided by the European Opendata Portal: CORDIS opendata.
Architecture and regulation of PI3KC2β lipid kinase complex for nutrient signaling at the lysosome
Read MoreDissecting GLP-1 receptor internalization pathways using genetic and pharmacological tools
Read MoreLeveraging the potential of historical spy satellite photography for ecology and conservation
Read More